Cargando…

NDRG1 in Cancer: A Suppressor, Promoter, or Both?

SIMPLE SUMMARY: NDRG1 (N-myc downregulated gene-1) has been reported to suppress metastasis, to be a biomarker of poor outcome, and to be a facilitator of disease progression in a range of different cancers. Characterizing NDRG1 remains challenging due to its pleiotropic functions. This review summa...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Vaibhavi, Lakhani, Sunil R., McCart Reed, Amy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737586/
https://www.ncbi.nlm.nih.gov/pubmed/36497221
http://dx.doi.org/10.3390/cancers14235739
_version_ 1784847327427559424
author Joshi, Vaibhavi
Lakhani, Sunil R.
McCart Reed, Amy E.
author_facet Joshi, Vaibhavi
Lakhani, Sunil R.
McCart Reed, Amy E.
author_sort Joshi, Vaibhavi
collection PubMed
description SIMPLE SUMMARY: NDRG1 (N-myc downregulated gene-1) has been reported to suppress metastasis, to be a biomarker of poor outcome, and to be a facilitator of disease progression in a range of different cancers. Characterizing NDRG1 remains challenging due to its pleiotropic functions. This review summarizes the role of NDRG1 in cancer and provides an overview of its expression and function in different cancer types. ABSTRACT: N-myc downregulated gene-1 (NDRG1) has been variably reported as a metastasis suppressor, a biomarker of poor outcome, and a facilitator of disease progression in a range of different cancers. NDRG1 is poorly understood in cancer due to its context-dependent and pleiotropic functions. Within breast cancer, NDRG1 is reported to be either a facilitator of, or an inhibitor of tumour progression and metastasis. The wide array of roles played by NDRG1 are dependent on post-translational modifications and subcellular localization, as well as the cellular context, for example, cancer type. We present an update on NDRG1, and its association with hallmarks of cancer such as hypoxia, its interaction with oncogenic proteins such as p53 as well its role in oncogenic and metastasis pathways in breast and other cancers. We further comment on its functional implications as a metastasis suppressor and promoter, its clinical relevance, and discuss its therapeutic targetability in different cancers.
format Online
Article
Text
id pubmed-9737586
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97375862022-12-11 NDRG1 in Cancer: A Suppressor, Promoter, or Both? Joshi, Vaibhavi Lakhani, Sunil R. McCart Reed, Amy E. Cancers (Basel) Review SIMPLE SUMMARY: NDRG1 (N-myc downregulated gene-1) has been reported to suppress metastasis, to be a biomarker of poor outcome, and to be a facilitator of disease progression in a range of different cancers. Characterizing NDRG1 remains challenging due to its pleiotropic functions. This review summarizes the role of NDRG1 in cancer and provides an overview of its expression and function in different cancer types. ABSTRACT: N-myc downregulated gene-1 (NDRG1) has been variably reported as a metastasis suppressor, a biomarker of poor outcome, and a facilitator of disease progression in a range of different cancers. NDRG1 is poorly understood in cancer due to its context-dependent and pleiotropic functions. Within breast cancer, NDRG1 is reported to be either a facilitator of, or an inhibitor of tumour progression and metastasis. The wide array of roles played by NDRG1 are dependent on post-translational modifications and subcellular localization, as well as the cellular context, for example, cancer type. We present an update on NDRG1, and its association with hallmarks of cancer such as hypoxia, its interaction with oncogenic proteins such as p53 as well its role in oncogenic and metastasis pathways in breast and other cancers. We further comment on its functional implications as a metastasis suppressor and promoter, its clinical relevance, and discuss its therapeutic targetability in different cancers. MDPI 2022-11-22 /pmc/articles/PMC9737586/ /pubmed/36497221 http://dx.doi.org/10.3390/cancers14235739 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Joshi, Vaibhavi
Lakhani, Sunil R.
McCart Reed, Amy E.
NDRG1 in Cancer: A Suppressor, Promoter, or Both?
title NDRG1 in Cancer: A Suppressor, Promoter, or Both?
title_full NDRG1 in Cancer: A Suppressor, Promoter, or Both?
title_fullStr NDRG1 in Cancer: A Suppressor, Promoter, or Both?
title_full_unstemmed NDRG1 in Cancer: A Suppressor, Promoter, or Both?
title_short NDRG1 in Cancer: A Suppressor, Promoter, or Both?
title_sort ndrg1 in cancer: a suppressor, promoter, or both?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737586/
https://www.ncbi.nlm.nih.gov/pubmed/36497221
http://dx.doi.org/10.3390/cancers14235739
work_keys_str_mv AT joshivaibhavi ndrg1incancerasuppressorpromoterorboth
AT lakhanisunilr ndrg1incancerasuppressorpromoterorboth
AT mccartreedamye ndrg1incancerasuppressorpromoterorboth